Inhibikase Therapeutics Inc (Nasdaq: IKT), a US-based clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, announced on Thursday that it has received a USD385,388 research grant from the United States National Institute of Neurological Disease and Stroke to assess the therapeutic potential of IkT-148009, the company's lead c-Abl inhibitor, in a novel preclinical model for Multiple System Atrophy.
The grant is intended to enable Inhibikase to assess the mechanism of the Multiple System Atrophy disease process in a novel rodent model to determine if the product could have the same therapeutic impact on the disease process as it has in models of Parkinson's disease.
The product is a selective c-Abl kinase inhibitor that inhibits c-Abl and the closely related Abl2/Arg enzyme without inhibition of other members of the Abl-kinase family called c-Kit or PDGFRa/b. It has around 20 times the potency of the anticancer agent Imatinib against c-Abl in enzyme inhibition assays.
Merck partners with Isomorphic Labs on AI-driven oncology drug discovery
Dicot Pharma secures EU approval to advance LIB-01 phase 2b study
NFL Biosciences enrolls first participant in Phase 2 smoking cessation trial
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial